Literature DB >> 18524418

What does it take to stay healthy past 100?: Commentary on "No disease in the brain of a 115-year-old woman".

Joseph L Price1.   

Abstract

The description of an 115-year-old woman without dementia or Alzheimer's disease (AD) is remarkable, but fits well with previous accounts of aging and AD. Several similar non-demented cases aged 85-105 years have been reported previously, who had neurofibrillary tangles in the medial temporal lobe, but no deposition of amyloid plaques. Together with observations on other aging and very mild AD cases, these can be related to a model of aging and AD. In this model, tangles develop independently but relatively slowly during aging; these represent neurodegeneration, but by themselves may not represent AD. In contrast, amyloid may be the driving factor in AD, exacerbating neurofibrillary changes and other neurodegeneration. There is a pre-clinical period when the process has begun but has not produced sufficient degeneration to produce clinical symptoms. Critical questions raised by the present report include what genetic or other factors allowed healthy survival to age 115 year, and whether anti-amyloid therapies will allow more general survival in good mental health beyond age 100?

Entities:  

Mesh:

Year:  2008        PMID: 18524418      PMCID: PMC2493610          DOI: 10.1016/j.neurobiolaging.2008.04.011

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  29 in total

Review 1.  Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein.

Authors:  D J Selkoe
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 2.  Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease.

Authors:  Sam Gandy
Journal:  Neurobiol Aging       Date:  2002 Nov-Dec       Impact factor: 4.673

Review 3.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

Review 4.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease.

Authors:  J C Morris; J L Price
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

5.  Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.

Authors:  J L Price; A I Ko; M J Wade; S K Tsou; D W McKeel; J C Morris
Journal:  Arch Neurol       Date:  2001-09

6.  Dementia and Alzheimer disease incidence: a prospective cohort study.

Authors:  Walter A Kukull; Roger Higdon; James D Bowen; Wayne C McCormick; Linda Teri; Gerard D Schellenberg; Gerald van Belle; Lance Jolley; Eric B Larson
Journal:  Arch Neurol       Date:  2002-11

7.  Absence of cognitive impairment or decline in preclinical Alzheimer's disease.

Authors:  W P Goldman; J L Price; M Storandt; E A Grant; D W McKeel; E H Rubin; J C Morris
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

Review 8.  Disease modifying therapy for AD?

Authors:  Todd E Golde
Journal:  J Neurochem       Date:  2006-11       Impact factor: 5.372

9.  Incidence and prevalence of dementia in the Cardiovascular Health Study.

Authors:  Annette L Fitzpatrick; Lewis H Kuller; Diane G Ives; Oscar L Lopez; William Jagust; John C S Breitner; Beverly Jones; Constantine Lyketsos; Corinne Dulberg
Journal:  J Am Geriatr Soc       Date:  2004-02       Impact factor: 5.562

Review 10.  Apolipoprotein E, amyloid, and Alzheimer disease.

Authors:  K R Bales; J C Dodart; R B DeMattos; D M Holtzman; S M Paul
Journal:  Mol Interv       Date:  2002-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.